Teva Pharmaceutical Industries Limited (TEVA)
-NYSE | Prev Close: | 37.69 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 44.25 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 36.63 - 42.83 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 3,353,050 |
|---|
| Market Cap: | 31.85B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Teva says oral MS drug laquinimod may reduce brain tissue damageReuters(Tue, Oct 1)
- InPlay: Teva Pharma launches of generic Zemplar in the USBriefing.com(Tue, Oct 1)
- Teva Announces Launch of Generic Zemplar® in the United StatesBusiness Wire(Tue, Oct 1)
- Newly Published Phase III Exploratory Analysis Suggests Investigational Oral Laquinimod for Multiple Sclerosis May Reduce Brain Damage Caused by NeurodegenerationThomson Reuters ONE(Tue, Oct 1)
- Newly Published Phase III Exploratory Analysis Suggests Investigational Oral Laquinimod for Multiple Sclerosis May Reduce Brain Damage Caused by NeurodegenerationBusiness Wire(Tue, Oct 1)
- Outperforming the Market in Uncertain Timesat Motley Fool(Mon, Sep 30)
- Exclusive Generic Launches at TevaZacks(Mon, Sep 30)
- Teva In-Focus: A New Webinar Series for the Investment Community Focusing on Teva’s R&D ActivitiesBusiness Wire(Mon, Sep 30)
- Will Galena's Initiatives Translate Into Positive Returns?at Seeking Alpha(Sat, Sep 28)
- 5 Stocks Growing Their Dividends by 20% Per Yearat Motley Fool(Sat, Sep 28)
- A Reshuffle in a $27 Billion Marketat Motley Fool(Sat, Sep 28)
- 3 Dividends Investors Loveat Motley Fool(Fri, Sep 27)
- Will Teva Recover From Its Downfall?at Motley Fool(Fri, Sep 27)
- New Clinical Insights and Data Presented at 29th ECTRIMS Congress Further Advance Teva’s Leadership in Multiple SclerosisBusiness Wire(Thu, Sep 26)
- First Week of November 16th Options Trading For Teva Pharmaceutical Industries (TEVA)at Forbes(Wed, Sep 25)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| TEVA | 0.00% | 31.85B |
| NVO | 0.00% | 90.48B |
| AGN | 0.00% | 26.95B |
| FRX | 0.00% | 11.62B |
Key Statistics
| Forward P/E (1 yr): | 7.19 |
|---|
| P/S (ttm): | 1.59 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.00 |
|---|
| Quarterly EPS Est
(Sep-13)
: | 1.25 |
|---|
| Mean Recommendation*: | 2.6 |
|---|
| PEG Ratio (5 yr expected): | 3.19 |
|---|
Business Summary
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. It offers generic pharmaceutical products; and basic chemicals, as well as specialized product families, such as sterile pro...
View More
0.41%